Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium

Rhea-AI Summary

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced participation in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium from April 3-5, 2023. The event will feature fireside chats and panel discussions, including one titled “Targeted Therapies in AML”, led by Aptose's Chief Medical Officer, Rafael Bejar, M.D., Ph.D., on April 5 from 12:00 to 12:45 PM Eastern Time. Aptose specializes in developing oral kinase inhibitors for hematologic malignancies, with key candidates being tuspetinib and luxeptinib, aimed at addressing unmet clinical needs in oncology.

SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium being held April 3-5, 2023, in a virtual format.

The Cantor Healthcare Research team will be hosting a series of insightful fireside chats, panel presentations, and 1x1 meetings during the symposium. Aptose’s Chief Medical Officer, Rafael Bejar, M.D., Ph.D., will participate in a panel, “Targeted Therapies in AML.”

Cantor’s The Future of Oncology Virtual Symposium

Panel Title:	Targeted Therapies in AML
Date:	Wednesday, April 5, 2023
Time:	12:00 – 12:45 PM Eastern Time
Aptose Speaker:	Rafael Bejar, M.D., Ph.D., Senior Vice President and Chief Medical Officer

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com.

For further information, please contact:
Aptose Biosciences Inc.	LifeSci Advisors, LLC
Susan Pietropaolo	Dan Ferry, Managing Director
Investor Relations	617-535-7746
201-923-2049	Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com

 

FAQ

When will Aptose participate in the oncology symposium?

Aptose will participate in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium from April 3-5, 2023.

What is the panel topic Aptose's CMO will discuss?

Aptose's CMO, Rafael Bejar, will discuss “Targeted Therapies in AML” during a panel on April 5, 2023.

What time is Aptose's panel at the symposium?

The panel “Targeted Therapies in AML” is scheduled for April 5, 2023, from 12:00 to 12:45 PM Eastern Time.

What are the main products Aptose is developing?

Aptose is developing two oral kinase inhibitors: tuspetinib and luxeptinib for hematologic malignancies.

What is the focus area of Aptose Biosciences?

Aptose Biosciences focuses on precision oncology, specifically targeting unmet medical needs in hematology.